Educational content only. Not medical advice. The content creators are not doctors or medical professionals. Consult your healthcare provider before taking any action.
Quick answer
Semaglutide targets one receptor (GLP-1), tirzepatide two (GLP-1/GIP), and retatrutide three (GLP-1/GIP/glucagon). Across separate trials, more receptors tracked with greater average weight loss (~15% vs ~21% vs ~24–28%). Only semaglutide and tirzepatide are FDA-approved; retatrutide remains investigational and unavailable outside trials as of June 2026.
Retatrutide, tirzepatide, and semaglutide are incretin-based weight-management molecules that differ by how many hormone receptors they target. Semaglutide hits one (GLP-1), tirzepatide hits two (GLP-1/GIP), and retatrutide hits three (GLP-1/GIP/glucagon). In trials, higher receptor coverage tracked with larger average weight loss. Only semaglutide and tirzepatide are FDA-approved; retatrutide remains investigational as of June 2026.
Retatrutide vs tirzepatide vs semaglutide at a glance
| Semaglutide | Tirzepatide | Retatrutide | |
|---|---|---|---|
| Receptor targets | GLP-1 (single agonist) | GLP-1 + GIP (dual / "twincretin") | GLP-1 + GIP + glucagon (triple agonist) |
| Approved brand(s) | Wegovy (obesity), Ozempic (T2D) | Zepbound (obesity), Mounjaro (T2D) | None — investigational |
| Typical weekly dose (trials) | up to 2.4 mg (obesity) | up to 15 mg | up to 12 mg (phase 2/3) |
| Half-life | ~7 days (once-weekly) | ~5 days (once-weekly) | ~6 days (once-weekly) [VERIFY: exact retatrutide half-life] |
| Headline mean weight loss | −14.9% at 68 wk (STEP 1) | −20.9% at 72 wk (SURMOUNT-1) | −24.2% at 48 wk (phase 2); up to −28.3% at 80 wk (TRIUMPH-1) |
| FDA status (June 2026) | Approved | Approved | Not approved; phase 3 ongoing |
| Most common side effects | Nausea, diarrhea, constipation, vomiting | Nausea, diarrhea, constipation, vomiting | GI effects + dose-dependent heart-rate rise |
What is the difference between retatrutide, tirzepatide, and semaglutide?
The three molecules sit on a spectrum defined by how many incretin and metabolic hormone receptors each one activates. That single design choice — receptor count — is the cleanest way to understand why their trial outcomes differ.
Semaglutide is a single agonist. It mimics glucagon-like peptide-1 (GLP-1), a gut hormone that slows gastric emptying, increases satiety, and stimulates glucose-dependent insulin secretion. In the STEP 1 trial, once-weekly semaglutide 2.4 mg produced a mean body-weight reduction of 14.9% at 68 weeks, versus 2.4% for placebo (Wilding et al., 2021, N Engl J Med, PMID 33567185).
Tirzepatide is a dual agonist — often called a "twincretin" — that activates both GLP-1 and the glucose-dependent insulinotropic polypeptide (GIP) receptor. Adding GIP appears to amplify the metabolic effect. In SURMOUNT-1, tirzepatide 15 mg produced a mean weight reduction of 20.9% at 72 weeks versus 3.1% for placebo (Jastreboff et al., 2022, N Engl J Med, PMID 35658024).
Retatrutide is a triple agonist that adds the glucagon receptor to GLP-1 and GIP. Glucagon-receptor activity is the differentiator: beyond appetite suppression, glucagon agonism is thought to increase energy expenditure and influence hepatic fat metabolism. Retatrutide (Eli Lilly's LY3437943) is an agonist of the GIP, GLP-1, and glucagon receptors (Jastreboff et al., 2023, N Engl J Med, PMID 37366315).
The practical takeaway: each added receptor in this lineup has, so far, been associated with a larger average weight reduction in trials — though these come from separate studies, not one direct three-way comparison. Retatrutide's extra glucagon activity also explains its distinct side-effect signal (resting heart-rate increase), covered below. To go deeper on the two approved drugs, see the tirzepatide protocol guide and semaglutide protocol guide.
How does each drug work (mechanism deep-dive)?
Semaglutide (GLP-1 single agonist)
Semaglutide is a long-acting GLP-1 receptor agonist engineered for once-weekly dosing through albumin binding. By engaging GLP-1 receptors in the pancreas, gut, and brain, it enhances glucose-dependent insulin release, suppresses glucagon when glucose is high, slows gastric emptying, and acts on hypothalamic appetite centers to reduce food intake. Beyond weight, semaglutide 2.4 mg reduced major adverse cardiovascular events (MACE) by 20% (hazard ratio 0.80) over a mean ~40 months in adults with established cardiovascular disease and overweight or obesity but without diabetes, in the SELECT trial (Lincoff et al., 2023, N Engl J Med, PMID 37952131). That cardiovascular outcome is a meaningful differentiator: it is the most established hard-endpoint data in this class.
Tirzepatide (GLP-1 + GIP dual agonist)
Tirzepatide adds GIP-receptor agonism to the GLP-1 mechanism. GIP is the other major incretin hormone; in the context of GLP-1 co-agonism, GIP activity appears to further improve insulin sensitivity, lipid handling, and satiety signaling. In a direct head-to-head in type 2 diabetes (SURPASS-2), tirzepatide 15 mg lowered HbA1c by 2.30 percentage points versus 1.86 for semaglutide 1 mg, and produced greater weight loss (Frías et al., 2021, N Engl J Med, PMID 34170647). The dual mechanism is why tirzepatide tends to outperform a GLP-1-only agent on both glucose and weight endpoints.
Retatrutide (GLP-1 + GIP + glucagon triple agonist)
Retatrutide layers glucagon-receptor agonism on top of the GLP-1/GIP "twincretin" platform. Glucagon agonism is counterintuitive for a weight drug — glucagon raises blood sugar — but at balanced co-agonist ratios it is thought to increase resting energy expenditure and drive hepatic fat mobilization while the GLP-1/GIP components control appetite and glucose. The hepatic effect is striking: in a phase 2a study of metabolic dysfunction-associated steatotic liver disease (MASLD), retatrutide reduced relative liver-fat content by roughly 86% at 48 weeks at the highest dose, with most participants reaching normal liver fat (Sanyal et al., 2024, Nat Med, PMC11271400 / PMID 38858523). The trade-off is that glucagon agonism also drives a dose-dependent rise in resting heart rate, a signal not prominent with semaglutide or tirzepatide.
How do the weight-loss results compare?
The most important caveat first: there is no single head-to-head trial of all three drugs. The percentages below come from separate, differently designed studies with different durations, populations, and dose-escalation schedules. Cross-trial comparison suggests a clear ranking, but it is indirect for retatrutide.
Semaglutide — STEP 1. Mean weight reduction of −14.9% at 68 weeks (semaglutide 2.4 mg) versus −2.4% for placebo; ~15.3 kg lost on drug (Wilding et al., 2021, N Engl J Med, PMID 33567185).
Tirzepatide — SURMOUNT-1. Mean weight reductions of −15.0% (5 mg), −19.5% (10 mg), and −20.9% (15 mg) at 72 weeks, versus −3.1% for placebo (Jastreboff et al., 2022, N Engl J Med, PMID 35658024).
Tirzepatide vs semaglutide — SURMOUNT-5 (the one real head-to-head among the approved pair). In a direct comparison in adults with obesity but without diabetes, tirzepatide produced −20.2% versus −13.7% for semaglutide at 72 weeks (P<0.001), confirming tirzepatide's superiority over semaglutide for weight loss (Aronne et al., 2025, N Engl J Med, PMID 40353578).
Retatrutide — phase 2. Mean reductions of −8.7% (1 mg), −17.1% (4 mg), −22.8% (8 mg), and −24.2% (12 mg) at 48 weeks, versus −2.1% for placebo (Jastreboff et al., 2023, N Engl J Med, PMID 37366315).
Retatrutide — phase 3 (TRIUMPH-1). Lilly's pivotal phase 3 obesity trial (NCT05929066) reported mean reductions of approximately −19.0% (4 mg), −25.9% (9 mg), and −28.3% (12 mg) at 80 weeks, with a substantial fraction of participants reaching ≥30% weight loss (ClinicalTrials.gov, NCT05929066; topline results reported May 2026). [VERIFY: exact TRIUMPH-1 per-dose percentages and ≥30% responder rate against the peer-reviewed publication when available — figures are from topline announcements, not yet a primary journal article.]
Read carefully, the indirect pattern is consistent: single-agonist (≈15%) < dual-agonist (≈21%) < triple-agonist (≈24–28%). But retatrutide's edge over tirzepatide has not been established in a direct comparison, and longer trials sometimes regress toward the mean. Treat the retatrutide numbers as promising-but-unconfirmed-by-direct-comparison.
When should you consider one over another (decision matrix)?
This section is educational framing, not a recommendation. Drug selection is a clinical decision. Consult your healthcare provider before starting any peptide or incretin protocol.
| Scenario | What the evidence points toward |
|---|---|
| Want an FDA-approved option with the strongest cardiovascular outcome data | Semaglutide — SELECT showed a 20% MACE reduction (Lincoff et al., 2023). |
| Want the largest weight loss among approved drugs | Tirzepatide — beat semaglutide directly in SURMOUNT-5 (Aronne et al., 2025). |
| Type 2 diabetes plus weight, want best glucose + weight combined | Tirzepatide — superior HbA1c and weight vs semaglutide in SURPASS-2 (Frías et al., 2021). |
| Significant hepatic steatosis (MASLD) is the primary concern | Retatrutide showed large liver-fat reductions in phase 2a (Sanyal et al., 2024) — but it is investigational and not available outside trials. |
| Want the highest potential weight loss and willing to wait | Retatrutide — but it is not FDA-approved; access outside a registered trial is unregulated and risky. |
| History of significant tachyarrhythmia or heart-rate sensitivity | Discuss retatrutide's dose-dependent heart-rate increase with a provider; the GLP-1/GIP agents lack this signal at the same magnitude. |
For broader context on goal-based selection, see the fat-loss peptides hub and the longevity peptides hub.
How do the side effects compare?
All three share the incretin-class gastrointestinal profile — nausea, vomiting, diarrhea, and constipation — which is typically dose-dependent, most intense during dose escalation, and usually mild to moderate. The key differentiator is retatrutide's heart-rate signal.
| Side effect | Semaglutide | Tirzepatide | Retatrutide |
|---|---|---|---|
| Nausea | Common (most frequent AE) | Common | Common; rose from ~9% (placebo) to ~59% at 12 mg in phase 2 |
| Vomiting | Common | Common | Dose-dependent; up to ~39% at 12 mg in phase 2 |
| Diarrhea / constipation | Common | Common | Common |
| Resting heart-rate increase | Minimal | Minimal–modest | Dose-dependent rise (~4–6 bpm at high dose), peaking ~24 wk |
| Discontinuation for AEs | Low–moderate | Low–moderate | ~16% at 8–12 mg in phase 2 |
The retatrutide gastrointestinal and heart-rate figures are from the phase 2 obesity trial (Jastreboff et al., 2023, N Engl J Med, PMID 37366315). [VERIFY: exact per-dose nausea/vomiting/discontinuation percentages against the published supplementary appendix.] Across the class, GI adverse events occur mainly during titration and tend to ease over time.
Two class-wide cautions worth naming: incretin agents carry a boxed warning related to thyroid C-cell tumors observed in rodents (clinical relevance in humans is not established), and there are reports of gallbladder events and pancreatitis. None of these three should be combined with another GLP-1-class drug. Consult your healthcare provider before starting, stopping, or changing any protocol, and discuss your full medical history and current medications.
What do they cost, and can you actually get them (NYC)?
Pricing and access changed sharply in 2025–2026 as the compounding window closed.
Semaglutide and tirzepatide (approved). Both are available by prescription in New York. List prices for the branded obesity products historically ran north of $1,000/month before insurance and manufacturer savings programs; actual out-of-pocket cost depends heavily on coverage. During the 2022–2024 shortages, compounded versions were widely sold at roughly $150–$300/month, but that pathway has effectively closed.
The compounding crackdown. The FDA declared the tirzepatide and semaglutide shortages resolved (tirzepatide in late 2024, semaglutide in early 2025), which ended the legal basis for 503A pharmacies and 503B outsourcing facilities to compound "essentially a copy" of these drugs. Then, on April 30, 2026, the FDA proposed to exclude semaglutide, tirzepatide, and liraglutide from the 503B bulk drug substances list, stating it "did not identify a clinical need" for outsourcing facilities to compound them from bulk substance (FDA, "FDA Proposes to Exclude Semaglutide, Tirzepatide, and Liraglutide on 503B Bulks List," April 30, 2026). In practice: legitimate access to these two now runs through a prescription for the branded product.
Retatrutide (investigational). Retatrutide is not FDA-approved and cannot be legally compounded for human use. As of June 2026 it is in phase 3, with regulatory submission and potential approval projected for 2027–2028. [VERIFY: retatrutide NDA filing/approval timeline.] Products sold online as "research" retatrutide are unregulated gray- or black-market material with no guarantee of identity, purity, dose accuracy, or sterility; the FDA has issued warning letters and taken enforcement action against such sellers. The only lawful human exposure today is via a registered clinical trial or an expanded-access (compassionate use) authorization.
Legal status varies by jurisdiction; consult a lawyer for binding advice. For a current overview, see our peptide legal status 2026 explainer.
Can you stack or switch between them?
No — these three should not be combined. All act on the GLP-1 receptor (and tirzepatide and retatrutide also share GIP), so stacking any two would be pharmacologically redundant and would compound the dose-dependent gastrointestinal and (for retatrutide) cardiovascular effects rather than create useful synergy. There is no trial evidence supporting concurrent use, and doing so would meaningfully raise risk.
Switching between them (for example, semaglutide to tirzepatide) is done in clinical practice, but it is a provider-managed transition involving re-titration from a low dose to limit nausea — not a do-it-yourself swap. Because retatrutide is investigational, there is no approved or validated protocol for switching to or from it outside a trial setting. Consult your healthcare provider before combining, switching, or sequencing any of these medications.
Frequently asked questions
Q: Is retatrutide better than tirzepatide and semaglutide? A: In cross-trial terms, retatrutide produced the largest average weight loss (about 24% at 48 weeks in phase 2, and up to roughly 28% at 80 weeks in phase 3 topline data), versus about 21% for tirzepatide and 15% for semaglutide. But "better" is not settled: there is no direct head-to-head trial of retatrutide against the other two, and it carries a unique dose-dependent heart-rate increase. It also is not FDA-approved. Tirzepatide is the strongest proven weight-loss option among approved drugs, having beaten semaglutide directly in SURMOUNT-5.
Q: Is retatrutide FDA-approved or legal to buy in 2026? A: No. As of June 2026, retatrutide is investigational and not FDA-approved for any use. It cannot be legally compounded for human use while under patent and investigational status. The only lawful routes for human exposure are enrollment in a registered clinical trial or an expanded-access authorization. Products marketed online as "research" retatrutide are unregulated and may be contaminated, mislabeled, or counterfeit. Consult a healthcare provider and, for legal questions, a lawyer.
Q: Why does retatrutide cause a higher heart rate than the others? A: Retatrutide's third receptor target is the glucagon receptor. Glucagon agonism is associated with increased energy expenditure and hepatic fat mobilization, but it also drives a dose-dependent rise in resting heart rate — roughly 4–6 beats per minute at the highest dose in the phase 2 trial, peaking around 24 weeks (Jastreboff et al., 2023). Semaglutide (GLP-1 only) and tirzepatide (GLP-1/GIP) do not produce this signal to the same degree. Anyone with cardiac history should discuss this specifically with a provider.
Q: How much more weight loss does each added receptor produce? A: Indirectly, the pattern across separate trials is roughly: single-agonist semaglutide ≈ 15%, dual-agonist tirzepatide ≈ 21%, triple-agonist retatrutide ≈ 24–28%. Each added receptor (GIP, then glucagon) tracked with a larger average reduction. Crucially, these figures come from different studies with different durations and populations — only the tirzepatide-vs-semaglutide gap has been confirmed in a direct head-to-head (SURMOUNT-5).
Q: Can I take semaglutide and tirzepatide together? A: No. Both activate the GLP-1 receptor, so combining them is redundant and stacks the gastrointestinal side-effect burden without added benefit. The same applies to combining either with retatrutide. There is no trial evidence supporting concurrent incretin-agonist use. Switching from one to another should be done as a provider-supervised, re-titrated transition — not a self-directed combination.
Q: What happened to compounded semaglutide and tirzepatide? A: The FDA declared the shortages resolved (tirzepatide in late 2024, semaglutide in early 2025), which ended the legal basis for pharmacies to compound copies. On April 30, 2026, the FDA proposed excluding both — plus liraglutide — from the 503B bulk substances list, finding no clinical need for outsourcing-facility compounding (FDA, April 30, 2026). The practical result is that legitimate access now means a prescription for the branded product.
Q: Does retatrutide help with fatty liver? A: In a phase 2a study of MASLD, retatrutide reduced relative liver-fat content by approximately 86% at 48 weeks at the highest dose, with most treated participants reaching normal liver fat (Sanyal et al., 2024, Nat Med). These are research findings in a trial setting, not an approved indication. Retatrutide is investigational and not available for clinical use outside trials. Consult your healthcare provider about evidence-based options for hepatic steatosis.
References
- Jastreboff AM, Kaplan LM, Frías JP, et al. Triple–Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial. N Engl J Med. 2023;389(6):514–526. PMID: 37366315. https://pubmed.ncbi.nlm.nih.gov/37366315/
- Aronne LJ, et al. Tirzepatide as Compared with Semaglutide for the Treatment of Obesity (SURMOUNT-5). N Engl J Med. 2025. PMID: 40353578. https://pubmed.ncbi.nlm.nih.gov/40353578/
- Jastreboff AM, Aronne LJ, Ahmad NN, et al. Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1). N Engl J Med. 2022;387(3):205–216. PMID: 35658024. https://pubmed.ncbi.nlm.nih.gov/35658024/
- Wilding JPH, Batterham RL, Calanna S, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1). N Engl J Med. 2021;384(11):989–1002. PMID: 33567185. https://pubmed.ncbi.nlm.nih.gov/33567185/
- Frías JP, Davies MJ, Rosenstock J, et al. Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes (SURPASS-2). N Engl J Med. 2021;385(6):503–515. PMID: 34170647. https://pubmed.ncbi.nlm.nih.gov/34170647/
- Lincoff AM, Brown-Frandsen K, Colhoun HM, et al. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes (SELECT). N Engl J Med. 2023;389(24):2221–2232. PMID: 37952131. https://pubmed.ncbi.nlm.nih.gov/37952131/
- Sanyal AJ, et al. Triple hormone receptor agonist retatrutide for metabolic dysfunction-associated steatotic liver disease: a randomized phase 2a trial. Nat Med. 2024. PMID: 38858523; PMC11271400. https://pmc.ncbi.nlm.nih.gov/articles/PMC11271400/
- ClinicalTrials.gov. A Master Protocol to Investigate the Efficacy and Safety of LY3437943 (Retatrutide) Once Weekly in Participants Without Type 2 Diabetes Who Have Obesity or Overweight (TRIUMPH-1). NCT05929066. https://clinicaltrials.gov/study/NCT05929066
- U.S. Food and Drug Administration. FDA Proposes to Exclude Semaglutide, Tirzepatide, and Liraglutide on 503B Bulks List. April 30, 2026. https://www.fda.gov/news-events/press-announcements/fda-proposes-exclude-semaglutide-tirzepatide-and-liraglutide-503b-bulks-list
Written By
Editorial team. We cite published research; we are not licensed clinicians and content is not medically reviewed.
Medical Disclaimer
The information on this website is for educational purposes only and is not medical advice. The content creators are not doctors or medical professionals. This content should not be used to diagnose, treat, cure, or prevent any disease. Always consult with a qualified healthcare provider before starting any new supplement, medication, or health protocol. You assume all risks associated with using this information.